STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Greg Verdine, a scientist-turned-biotech entrepreneur, is having a strong year as science he tried to propel forward nearly 15 years ago may be changing the pancreatic cancer treatment landscape.
- Parabilis Medicines, one of Verdine's ventures, went public in June in one of the biotech industry's largest IPOs in recent years.
- LifeMine, another Verdine-founded company, announced a $263 million funding round on Thursday to advance a drug Verdine believes could make organ transplants more viable.
- The LifeMine drug is also seen by Verdine as potentially helping people with autoimmune conditions.
Why it matters: Verdine's simultaneous wins at Parabilis (a marquee IPO) and LifeMine ($263M raised) demonstrate that biotech ventures rooted in long-bet science — his pancreatic cancer work dates back roughly 15 years — can mature into investor-backed commercial programs spanning oncology, transplantation, and autoimmune disease.
